Table 5.

CD95 and CD95L expression on CD4⁺ CCR5⁺ and CD4⁺ CCR3⁺ T lymphocytes

	CD4+ CCR5+		CD4+ CCR3+
	−	+	−	+
CD95 expression
Acute (A)	1·3 ± 0·3	16·7 ± 1·5*	1·5 ± 0·4	3·2 ± 0·5*
Healed (H)	1·8 ± 0·5	4·1 ± 1·9	1·2 ± 0·2	2·0 ± 0·3
CD95L expression
Acute (A)	3·6 ± 0·5*	5·2 ± 0·8*	1·0 ± 0·4	11·2 ± 1·1*
Healed (H)	1·9 ± 0·3	0·8 ± 0·2	1·1 ± 0·8	2·5 ± 1·1

Frozen PBMC from five VL patients, studied in acute and healed phases of disease, were cultured for 24 hr in medium alone (–) and in the presence of LAg (+) (2 × 10⁷ equivalent promastigotes). Cells were treated with anti-CD4⁺ monoclonal antibody IS3-conjugated, anti-CD95 PE-conjugated or biotin–streptavidin PE-conjugated anti-human CD95L, and anti-CCR3 or anti-CCR5 FITC-conjugated antibodies. Data are expressed as mean percentage ± SE.

^*P < 0·05: significantly different from healed subjects. Percentage of CD95 expression in five healthy controls (CTR): CD4⁺ CCR5⁺ (1·2 ± 0·3); CD4⁺ CCR3⁺ (0·2 ± 0·01). Percentage of CD95L expression in CTR: CD4⁺ CCR5⁺ (0·3 ± 0·03); CD4⁺ CCR3⁺ (0·5 ± 0·01).